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Introduction: The androgen receptor (AR) is widely expressed in breast cancers and has been proposed as a
therapeutic target in estrogen receptor alpha (ER) negative breast cancers that retain AR. However, controversy exists
regarding the role of AR, particularly in ER + tumors. Enzalutamide, an AR inhibitor that impairs nuclear localization of
AR, was used to elucidate the role of AR in preclinical models of ER positive and negative breast cancer.
Methods: We examined nuclear AR to ER protein ratios in primary breast cancers in relation to response to endocrine
therapy. The effects of AR inhibition with enzalutamide were examined in vitro and in preclinical models of ER positive
and negative breast cancer that express AR.
Results: In a cohort of 192 women with ER + breast cancers, a high ratio of AR:ER (≥2.0) indicated an over four fold
increased risk for failure while on tamoxifen (HR = 4.43). The AR:ER ratio had an independent effect on risk for failure
above ER % staining alone. AR:ER ratio is also an independent predictor of disease-free survival (HR = 4.04, 95% CI: 1.68,
9.69; p = 0.002) and disease specific survival (HR = 2.75, 95% CI: 1.11, 6.86; p = 0.03). Both enzalutamide and bicalutamide
inhibited 5-alpha-dihydrotestosterone (DHT)-mediated proliferation of breast cancer lines in vitro; however, enzalutamide
uniquely inhibited estradiol (E2)-mediated proliferation of ER+/AR + breast cancer cells. In MCF7 xenografts (ER+/AR+)
enzalutamide inhibited E2-driven tumor growth as effectively as tamoxifen by decreasing proliferation. Enzalutamide also
inhibited DHT- driven tumor growth in both ER positive (MCF7) and negative (MDA-MB-453) xenografts, but did so by
increasing apoptosis.
Conclusions: AR to ER ratio may influence breast cancer response to traditional endocrine therapy. Enzalutamide elicits
different effects on E2-mediated breast cancer cell proliferation than bicalutamide. This preclinical study supports the
initiation of clinical studies evaluating enzalutamide for treatment of AR+ tumors regardless of ER status, since it blocks
both androgen- and estrogen- mediated tumor growth.Introduction
In breast cancers, androgen receptor (AR) is more widely
expressed than estrogen receptor alpha (ER) or progester-
one receptor (PR), and AR has recently emerged as a use-
ful marker for the further refinement of breast cancer
subtype classification [1,2]. Of all 2,171 invasive breast
cancers in women enrolled in the Nurses' Health Study,
77% were positive for AR by immunohistochemistry [3].* Correspondence: Jennifer.Richer@ucdenver.edu
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reproduction in any medium, provided the orAmong the subtypes, 88% of ER+, 59% of HER2+, and
32% of triple-negative breast cancers (ER–/PR–/HER2–)
were positive for AR expression by immunohistochemistry
[3]. Similar to ER and PR, AR expression is associated
with a well-differentiated state [4] and with more indolent
breast cancers [5].
In ER + breast cancers, adjuvant treatment with the
competitive antagonist tamoxifen or aromatase inhibitors
(AIs), which block conversion of androgens to estrogens,
is generally effective for inhibiting disease progression.
However, 30 to 50% of all ER + tumors display de novo
resistance to traditional endocrine therapies and ultimatelyral Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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In ER + tumors that respond to neoadjuvant endocrine
therapy, we previously observed that AR mRNA and
protein expression decrease, while in tumors that fail to
respond AR mRNA does not decrease [8,9]. AR overex-
pression increases tamoxifen resistance in breast cancer
models in vitro and in vivo [10]. Thus, de novo or acquired
resistance to anti-estrogen therapies could result from
tumor cell adaptation from estrogen dependence to an-
drogen dependence. In mice, treatment with an AI mark-
edly elevated intratumoral testosterone concentrations in
dimethylbenz(a)anthracene-induced rat mammary tumors
[11]. In postmenopausal women with ER + breast cancer,
particularly those being treated with AIs, circulating levels
of estradiol (E2) are extremely low, while circulating
androgen levels are increased [12] since AIs block the
conversion of androgens to estrogen. Indeed, circulating
levels of testosterone, androstenedione, and dehydroepian-
drosterone sulfate (DHEA-S) increase in women on AI
therapy [13] as compared with pretreatment levels. Fur-
thermore, high levels of the adrenal androgen DHEA-S
before treatment are predictive of failure on AIs, and
circulating DHEA-S increased during treatment in
patients with tumors that failed to respond to AI
treatment [14].
A subset of ER– breast cancers (molecular apocrine or
luminal androgen receptor) retain AR [15-18] and have
a gene expression pattern that closely resembles that of
ER + breast cancers [2,19]. The anti-androgen bicaluta-
mide inhibits the growth of molecular apocrine cell lines
in vitro and in vivo, supporting the hypothesis that
anti-androgens may be useful targeted therapies for such
tumors [2,17,18,20]. Indeed, a phase II clinical trial
testing bicalutamide as treatment for ER–/AR + breast
cancers (NCT00468715) showed some efficacy [21].
Bicalutamide is a competitive antagonist that does
allow AR to bind DNA [22]; however, in the setting
of castrate-resistant prostate cancer, bicalutamide can
exhibit an antagonist-to-agonist shift as demonstrated
clinically by a decline in prostate-specific antigen follow-
ing bicalutamide (Casodex) withdrawal [23].
Enzalutamide (formerly MDV3100) is an AR signaling
inhibitor that binds AR with fivefold higher affinity than
bicalutamide, impairs AR nuclear translocation, and
lacks agonist activity at effective doses [20-23]. Enzaluta-
mide significantly improved overall survival in patients
with castrate-resistant prostate cancer and is an approved
agent for the treatment of patients with metastatic
castration-resistant prostate cancer [24]. In this study, we
examined the effect of enzalutamide in AR + breast cancer
models (ER + and ER–) and present the first preclinical evi-
dence that inhibition of AR with enzalutamide may be an
effective therapeutic strategy not only for ER–/AR + breast
cancers, but also for ER+/AR + tumors. We also presentclinical data which suggest that a high amount of AR rela-
tive to ER may be indicative of tumors that will have a less
than optimal response to traditional endocrine therapy.
Methods
Cell culture
The identities of all cell lines were authenticated by
DNA fingerprinting (Identifier Kit; Applied Biosystems,
Grand Island, NY, USA) within 6 months of use. The
BCK4 line is an ER+/AR + breast cancer line derived
recently from a pleural effusion and has a nearly normal
karyotype [25]. For the BCK4 cell line, the patient sample
was acquired under a University of Colorado Institutional
Review Board-approved tissue-acquisition protocol and
patient-informed consent was obtained to acquire blood
and tissue for research purposes. All other cell lines were
obtained from the American Type Culture Collection;
Manassas, Virginia, USA. BCK4 and MCF7 cells were
grown in minimum essential media, 5% fetal bovine
serum, non-essential amino acids, insulin and penicillin/
streptomycin, and ZR75 cells in the same media with the
addition of HEPES and L-glutamine. MCF7 cells express a
wild-type AR, albeit with a shortened CAG repeat [26]
that is often indicative of a more active receptor [27].
T47D cells were grown in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum,
L-glutamine penicillin/streptomycin. LNCaP cells were
grown in RPMI, 5% fetal bovine serum and penicillin/
streptomycin. All cells were grown in a 37°C incu-
bator with 5% carbon dioxide. MDA-MB-453 and
MDA-kb2 (a derivative of MDA-MB-453 stably ex-
pressing the AR-dependent MMTV-luciferase reporter
gene construct; American Type Culture Collection)
were cultured in Leibovitz’s L-15 media (Invitrogen,
Carlsbad, CA, USA) containing 10% fetal bovine
serum (Invitrogen) and penicillin/streptomycin. MCF7-
TGL cells were generated by stable infection with retro-
viral SFG-NES-TGL vector, encoding a triple fusion of
thymidine kinase, green fluorescent protein and luciferase
and sorted for green fluorescent protein.
Tumor studies
MCF7 experiments with enzalutamide delivered in rodent
chow were performed at the University of Colorado
Anschutz Medical Campus and approved by the University
of Colorado Institutional Animal Care and Use Committee
(IACUC protocol 83611(03)1E). The MDA-MB-453 xeno-
graft experiment in which enzalutamide was delivered by
oral gavage was performed by AntiCancer Inc., San Diego,
CA, USA and was approved by the Institutional Animal Care
and Use Committee of AntiCancer Inc. All animal
experiments were conducted in accordance with the
National Institutes of Health Guidelines of Care and Use of
Laboratory Animals.
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that stably express a triple fusion of thymidine kinase,
green fluorescent protein and luciferase (SFG-NES-TGL
retroviral vector) for in vivo imaging purposes were mixed
with Matrigel (BD Biosciences, Franklin Lakes, New Jersey,
USA) and injected into the fourth inguinal mammary fat
pad of female, ovariectomized athymic nu/nu or nonobese
diabetic (NOD)/SCID mice (Taconic, Germantown, NY
USA). At time of tumor injection, E2 pellets (60-day
release, 1.5 mg/pellet; Innovative Research of America,
Sarasota, Florida USA) or the nonaromatizable androgen
5-alpha-dihydrotestosterone (DHT) (8 mg/pellet, packed
and sealed in silastic tubing) were implanted sub-
cutaneously at the back of the neck. Tumor burden was
assessed using an in vivo imaging system or caliper
measurements (tumor volume was calculated as: length ×
width × depth/2). Once tumors were established, mice
were matched into groups based on the total tumor
burden as measured by in vivo imaging system or caliper.
Groups receiving tamoxifen had a 90-day release, 5
mg/pellet (Innovative Research of America) implanted
subcutaneously. Mice were administered enzalutamide in
their chow (approximately a 50 mg/kg daily dose) or by
oral gavage (10 or 25 mg/kg/day). Enzalutamide was mixed
with ground mouse chow (catalog number AIN-76;
Research Diets Inc., New Brunswick, NJ, USA) at 0.43
mg/g chow. The feed was irradiated and stored at 4°C
before use. Mice in the control group received the same
ground mouse chow but without enzalutamide. All mice
were given free access to enzalutamide formulated chow or
control chow during the entire study period and at an
average of 3.5 g/day food intake. Feed was changed in the
animal cages twice a week. Water and feed were prepared
ad libitum. Two hours prior to sacrifice, mice were
injected intraperitoneally with 50 mg/kg bromodeoxyuri-
dine (BrdU; Sigma-Aldrich, St. Louis, MO, USA). Mice
were euthanized by carbon dioxide asphyxiation followed
by cervical dislocation, and the blood, tumors, colon, uteri
and mammary glands were harvested.
For the MDA-453 tumor study, 6 × 106 cells were
injected into the fourth inguinal mammary fat pad of
NOD-SCID-IL2Rgc−/− female mice into which a DHT
pellet (1.5 mg 60-day release; Innovative Research of
America) was implanted subcutaneously. The tumor size
was measured using calipers, and when tumors reached
100 mm3 the mice began receiving 10 mg/kg enzaluta-
mide or vehicle by oral gavage. Once the tumors reached
400 mm3, another group was started on 25 mg/kg enza-
lutamide. At the end of the experiment, tumors were
weighed and processed for embedding.
Neoadjuvant endocrine therapy study
The inclusion criteria and trial design are described
elsewhere [8,9]. Briefly, women with ER + breast cancerswere enrolled in a randomized phase II clinical trial to
receive exemestane alone (25 mg daily) or exemestane in
combination with tamoxifen (20 mg daily) for 4 months
prior to surgery. Women included in the trial were post-
menopausal with newly diagnosed cancers of stage II/III,
T2 to T3. Core needle biopsies were taken prior to treat-
ment and tumor pieces from the final excision surgery
were taken for analysis. The protocol was approved by
the Colorado Multiple Institutional Review Board and
informed consent was provided by all patients. The
criteria for responders ranged from minor response to
complete response, while nonresponders had stable or
progressive disease.
Tamoxifen study
This study included 192 female patients diagnosed with
ER + breast cancer at the Massachusetts General Hospital
(Partners) between 1977 and 1993, who were offered
tamoxifen treatment as part of their adjuvant therapy and
were followed at the hospital through 1998. Patients were
offered tamoxifen based on estrogen positivity (≥10 pmol/
mg protein) determined using either a ligand binding
assay or a radioactive enzyme-linked immunosorbent
assay, the standard protocol in use during this time period.
As part of the present study, archival formalin-fixed
paraffin-embedded tumors collected under the Institu-
tional Review Board protocol Molecular and Cellular
Predictors of Breast Cancer were stained for AR and ER
by immunohistochemistry. All slides were evaluated and
the percentage and intensity of both AR and ER were
recorded. Each slide was also scored using the Allred
scoring method.
Contingency tables were used to study the associations
between the AR/ER ratio and clinicopathologic variables.
In this analysis, each clinicopathologic variable was
divided into two or three categories (lymph node nega-
tive vs. lymph node positive; lymph node negative vs.
one to three positive vs. four or more positive; patient
age <50 years vs. ≥50 years; tumor size ≤2 cm vs. >2 cm;
grade 1 vs. grade 2 vs. grade 3; PR negative vs. positive;
ErbB2 ≤30% vs. >30%, MIB-1 <median vs. ≥median,
mitoses/10 high-powered fields (mitotic index) < median
vs. ≥median, epidermal growth factor receptor < median
vs. ≥median). Patients were followed from the date of
diagnosis to the date of first failure (local recurrence or
distant metastasis) as well as the date of death or last
follow-up. Patients who died of causes other than breast
cancer and patients who were lost to follow-up or whose
last encounter was before the end of the study were
censored at the date of death or last encounter for sur-
vival analyses. The AR:ER ratio was calculated using a
manual receiver operator characteristic analysis where
we investigated the ratio that produced the best differ-
ence between good and poor prognosis in relation to
Cochrane et al. Breast Cancer Research 2014, 16:R7 Page 4 of 19
http://breast-cancer-research.com/content/16/1/R7disease-free survival (DFS) to identify the cutoff point
for this variable. The final AR:ER ratio cutoff point was
determined to be 2.0. A Fisher’s exact test was used for
all dichotomized variables and the chi-square test for all
trichotomized variables to compare the AR:ER ratio with
other predictive markers. Kaplan–Meier curves used the
calculated AR:ER ratio. All statistics were calculated
using SAS (version 9.3; SAS Institute, Cary, NC, USA).
Significance was determined at P <0.05 and all tests were
two-sided.
Immunohistochemistry
Slides were deparaffinized in a series of xylenes and etha-
nols, and antigens were heat retrieved in either 10 mM
citrate buffer pH 6.0 (BrdU, Ki67) or 10 mM Tris/1 mM
ethylenediamine tetraacetic acid buffer at pH 9.0 (AR, ER,
caspase 3). Tissue for BrdU was incubated in 2 N HCl
followed by 0.1 M sodium borate following antigen
retrieval. Antibodies used were: AR clone 441 and ER
clone 1D5 (Dakocytomation, Carpinteria, CA, USA),
cleaved caspase 3 (Cell Signaling Technology, Danvers,
MA, USA), Ki67 (sc-15402; Santa Cruz, Dallas, TX, USA)
and BrdU (BD Biosciences, Franklin Lakes, NJ, USA).
Envision horseradish peroxidase (Dakocytomation) was
used for antibody detection.
Terminal deoxynucleotidyl transferase dUTP nick
end-labeling (TUNEL) staining for apoptosis was per-
formed using the ApopTag Plus Peroxidase In Situ
Apoptosis Detection Kit (Millipore, Billerica, MA, USA),
as per the manufacturer’s instructions. AR and ER stain-
ing was assessed by a pathologist (PJ or ADT) and the
score is reported as intensity multiplied by percent posi-
tive cells, or in the case of the tamoxifen-treated cohort
the Kaplan–Meier curve is based on percent positive
cells, although results are similar and still significant
when the intensity is multiplied by the percent positive
cells. For ER, BrdU and TUNEL staining in xenograft
studies, three separate 200× fields of each xenograft
tumor were taken using an Olympus BX40 microscope
(Center Valley, PA, USA) with a SPOT Insight Mosaic
4.2 camera and software (Diagnostic Instruments, Inc.,
Sterling Heights, MI, USA). A color threshold (RGB for
positive staining nuclei, and HSB for total nuclei) was ad-
justed manually using ImageJ (National Institutes of
Health, Bethesda, MD, USA) for each image, and particles
created by the thresholds were analyzed for total area. The
RGB area was divided by the HSB area and multiplied by
100 for each image. For analysis of the nuclear androgen
receptor, cleaved caspase 3 and Ki67, slides were scanned
at 20× on an Aperio Scan ScanScope XT, Leica Microsys-
tems Inc. Buffalo Grove, IL United States. Mammary
tumor tissue was traced separately for each tumor and
necrotic areas of the tumor removed using a negative pen
tool in Aperio’s Scanscope software. A nuclear algorithmwas utilized to measure the percent positive cells for the
Ki-67-stained and AR-stained slides and the data were
exported. Cleaved caspase 3-stained slides were analyzed
using a modified positive pixel count algorithm.
Immunoblotting
Whole cell protein extracts (50 μg) were denatured,
separated on SDS-PAGE gels and transferred to poly-
vinylidene fluoride membranes. After blocking in 3%
bovine serum albumin in Tris-buffered saline–Tween,
membranes were probed overnight at 4°C. Primary
antibodies utilized include: ERα (Ab-16, 1:400 dilution;
Neomarkers, Fremont, CA USA), AR (PG-21, 1:400 dilu-
tion; Millipore (Bedford, Massachusetts USA) or EP6704,
1:10,000; Abcam (San Francisco, CA USA), glyceraldehyde
3-phosphate dehydrogenase (1:20,000 dilution; Sigma, St.
Louis, MO USA), Topo 1 (C-21, 1:100 dilution; Santa
Cruz) and alpha-tubulin (clone B-5-1-2, 1:30,000 dilution;
Sigma). After incubation with appropriate secondary anti-
body, results were detected using Western Lightning
Chemiluminescence Reagent Plus (Perkin Elmer, Waltham
Massachusetts USA).
Cellular fractionation
For the MDA-kb2 cellular fractionation, cells were
washed with ice-cold Dulbecco’s phosphate-buffered
saline, pH 7.4, pelleted using centrifugation and resus-
pended in 2 volumes of ice-cold NSB (10 mM Tris · Cl,
pH 7.4, 10 mM NaCl, 2 mM MgCl2, 1× protease inhibi-
tors). The volume was adjusted with ice-cold NSB to 15
times the initial volume and incubated for 30 minutes
on ice. The cytoplasmic fraction was obtained by
addition of NP-40 to a final concentration of 0.3%.
Nuclei and cytoplasm were separated using a 0.4 mm
clearance Dounce homogenizer. After centrifugation, the
supernatant containing the cytoplasmic fraction was
collected. The pellet containing the nuclear fraction was
resuspended in a 250 mM sucrose solution containing
10 mM MgCl2 and then 1 volume was added to 880 mM
sucrose containing 5 mM MgCl2 under the nuclear frac-
tion. The nuclei were then purified by centrifugation
through the sucrose cushion. For the MCF7s cells, cellular
fractionation was performed using the NE-PER Nuclear
and Cytoplasmic Extraction Kit, Pierce Biotechnology,
Rockford, IL USA as per the manufacturer’s instructions.
Nuclear translocation assay
MDA-kb2 cells were seeded at 2 × 103 cells/cm2 in
optical microplates in Leibovitz’s L-15 medium supple-
mented with 5% charcoal-stripped serum. After 3 days
of cultivation the cells were pretreated with enzaluta-
mide (1 or 10 μM) for 2 hours and then co-treated with
1 nM DHT for 1 hour in the presence of enzalutamide
(total 3 hours of treatment with enzalutamide). The cells
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4% formaldehyde for 30 minutes at room temperature
and permeabilized with 0.2% triton X-100. Samples were
then blocked with 5% bovine serum albumin for 1 hour
and incubated with an antibody against AR (N20, sc-815
1:100; Santa Cruz) in phosphate-buffered saline 0.1%
triton overnight. Incubation with the secondary antibody
anti-rabbit Alexa Fluor 488 (1:1,000) was performed in
2.5% bovine serum albumin for 2 hours at ambient
temperature. The nuclei were stained with 4',6-dia-
midino-2-phenylindole (1 μg/ml) for 30 minutes. Cells
were visualized with a 60× objective and a Qimaging
digital camera coupled to an Olympus X71 fluorescence
microscope using a yellow fluorescent protein filter
(Chroma U-N31040; Center Valley, PA, USA). The nu-
clear distribution of AR (ratio of nuclear AR signal/total
AR signal) was quantified in a minimum of 48 cells
using ImageJ software (National Institutes of Health).Real-time quantitative polymerase chain reaction
cDNA was synthesized from 1 μg total RNA, using M-Mulv
reverse transcriptase enzyme (Promega, Fitchburg, WI,
USA). For FASN, PRLR and GCDFP-15, SYBR green quanti-
tative gene expression analysis was performed using the fol-
lowing primers: FASN forward, 5′-AAGGACCTGTCTGG
ATTTGATGC-3′ and FASN reverse, 5′-TGGCTTCATAG
GTGACTTCCA-3′; PRLR forward, 5′-TATTCACTGACT
TACCACAGGGA-3′ and PRLR reverse, 5′-CCCATCTGG
TTAGTGGCATTGA-3′; GCDFP-15 forward, 5′-TCCCA
AGTCAGTACGTCCAAA-3′ and GCDFP-15 reverse, 5′-
CTGTTGGTGTAAAAGTCCCAG-3′; and 18S forward,
5′-TTGACGGAAGGGCACCACCAG-3′ and 18S reverse,
5′-GCACCACCACCCACGGAATCG-3′. For PR and stro-
mal cell-derived factor 1 (SDF-1, also known as CXCL12),
Taqman real-time polymerase chain reaction was performed
using validated primer/probe sets from Applied Biosystems
(assay ID: PR Hs01556702_m1, SDF-1 Hs00171022_m1,
18S Hs99999901_s1). Relative gene expression calculated
using the comparative cycle threshold method and values
were normalized to 18S.Luciferase assays
MDA-kb2 cells were plated at 5 × 103 cells/well in 96-
well luminescence plates and incubated overnight. Cells
were treated with 10-fold serial dilutions of enzalutamide
(10, 1, 0.1 μM) and DHT (10, 1, 0.1, 0.01, 0.001 nM) that
were prepared in dimethylsulfoxide. Following 24 hours of
incubation, the luminescence levels were determined with
the luciferase assay system (Promega). Three independent
experiments were performed and the luminescence values
were determined as relative units and normalized to
vehicle. Values are expressed as the mean fold induc-
tion ± standard error.Results
A new method to examine AR relative to ER
To test the significance of AR and ER expression in breast
cancer, we examined primary tumors from a group of
tamoxifen-treated patients with clinical outcome data.
This study included a cohort of 192 female patients diag-
nosed with breast cancer at the Massachusetts General
Hospital (Partners) between 1977 and 1993, treated with
adjuvant tamoxifen and followed at the hospital through
1998 under Institutional Review Board approval. The
women ranged in age from 20 to 91 years at the time of
cancer diagnosis with a median age of 68 years. Forty-
eight (25.0%) of the women failed tamoxifen therapy.
Women who relapsed while on tamoxifen were generally
younger (median 64 years vs. 70 years for nonfailures,
P = 0.007), had larger tumors (median 2.6 vs. 1.9 cm3;
P = 0.003), had a higher proportion of grade 3 tumors
(45.8% vs. 29.4%; P = 0.034), had more positive lymph
nodes (median 2 vs. 1; P = 0.006), had a higher mi-
totic index (median 5 vs. 4; P = 0.007), and had lower
levels of PR staining (median 5% vs. 45%, P = 0.048).
There were no differences in MIB-1, HER2, or epidermal
growth factor receptor staining percentages between the
two groups. Women who failed had a median ER percent
cells positive of 62.5%. This was significantly lower than
the 92.5% percent cells positive in tumors that did not fail
(P = 0.001). Although the AR percent cells positive was
higher in tumors of women who failed (70% vs. 57.5% for
nonfailures), the difference in AR staining percentage did
not reach statistical significance.
Since we had previously observed that AR mRNA and
protein decrease with treatment in tumors responsive to
neoadjuvant endocrine therapy, but did not decrease in
nonresponsive tumors [8,9] (Figure S1, left in Additional
file 1), we decided to examine nuclear AR as compared
with ER. The median AR:ER ratio in pretreatment biopsies
of responsive tumors (Figure S1A in Additional file 1) in
the neoadjuvant study was 1.00, with a statistically signifi-
cant positive correlation between AR and ER expression
(P = 0.006) (Figure S1A in Additional file 1). However, in
nonresponsive tumors (Figure S1B in Additional file 1),
the median AR:ER ratio was 3.79 with no significant
correlation between AR and ER. Interestingly, in adjacent
uninvolved epithelium (Figure S1C in Additional file 1),
the median ratio of AR to ER expression was 0.94, again
with a significant positive correlation between the two
receptors (P = 0.0003).
Based on these intriguing results in the small neoadju-
vant study, we decided to examine the amount of AR
relative to ER in the larger cohort of 192 female patients
diagnosed with ER + breast cancer that received adjuvant
tamoxifen therapy. To identify the best cutoff point for
separating patients into good and poor survival, a manual
receiver operator characteristic analysis based on time to
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the AR:ER ratio – and the optimal cutoff point of 2.0 was
determined. In addition, since the AR:ER ratio was not in
a log-linear relationship with the hazard function, it
was necessary to use the dichotomized variable in the
Cox proportional hazard models. Both AR percent
cell staining and ER percent cell staining contribute
to the AR:ER ratio. AR showed strong positive correl-
ation (r = 0.86, P < 0.0001) with the ratio, while ER showed
moderate negative correlation (r = −0.36, P < 0.0001). The
AR:ER ratio with a cutoff value of 2.0 was significantly
different between the two groups (failed tamoxifen versus
nonfailed), with 27.1% of women who failed having
an AR:ER ratio >2.0 compared with only 6.3% of non-
failures (P < 0.0001).
High AR:ER ratio indicates poor response to traditional
endocrine therapy and overall survival
We compared the correlation between AR:ER ratio
(<2 or ≥2) with dichotomized study variables (Table 1).
Women with the higher AR:ER ratio are more likely
to have positive lymph nodes and are more likely to
fail on tamoxifen. Tumors from patients with lymph
node-negative disease who did not fail tamoxifen
therapy (no failure within 60 months of surgery) were
significantly more likely to have an AR:ER ratio less than
2.0 (P < 0.0001).
We then compared study variables with tamoxifen failure
by 5 years, and overall DFS and overall disease-specific
survival (DSS). By univariate analyses, the tumor size, ER
percent staining and AR:ER ratio were significantly associ-
ated with all survival outcomes (Table 2), while nodal posi-
tivity was significant only for tamoxifen failure and DFS.
Notably, the AR:ER ratio was the most significant markerTable 1 Comparison of AR:ER ratio to clinical and
pathologic variables
AR:ER <2 AR:ER ≥2 Chi-square
Variable n % n % P value
Age <50 170 7.6 22 13.6 0.34
Tumor size >2 cm 170 42.9 22 59.1 0.15
Tumor grade 2 + 3 169 91.1 22 100 0.15
Lymph node-positive 133 54.1 14 85.7 0.02
Failed tamoxifen treatment 170 20.6 22 59.1 <0.0001
AR-positive 170 88.2 22 100 0.09
Progesterone receptor-positive 123 83.7 8 75.0 0.52
MIB-1 ≥21.3 168 53.0 21 23.8 0.01
Mitotic index number >4 165 50.3 22 45.5 0.67
erbB2 >30% 149 8.1 20 20.0 0.09
EGFR-positive 147 16.3 19 10.5 0.51
AR, androgen receptor; EGFR, epidermal growth factor receptor; ER, estrogen
receptor. Bold data are significant.of poor survival (hazard ratio (HR) = 4.43 for tamoxifen
failure, P < 0.0001; HR = 4.40 for DFS, P < 0.0001; and
HR = 3.66 for DSS, P < 0.0001). In contrast, the ER
percent cell staining was associated with reduced risk
(HR = 0.98 for tamoxifen failure P < 0.0002; HR = 0.99 for
DFS, P < 0.0004; and HR = 0.99 for DSS, P < 0.0001) (see
Table 2 for 95% confidence intervals and Figure 1A,B for
Kaplan–Meier curves). A number of factors were inde-
pendently predictive of survival in a Cox proportional haz-
ards model. For tamoxifen failure these variables include
tumor size (HR = 1.92 for tumors >2 cm, P = 0.03),
lymph node positivity (HR = 3.41, P = 0.01), and ER
percent staining (HR = 0.98, P = 0.0002) (Table 2).
Figure 1 shows Kaplan–Meier curves with survival
separated into two groups: AR:ER ratios <2.0 (blue
squares) and those with ratios ≥2.0 (red circles). By the
end of 10 years, the observed DFS was 10% for patients
with a higher AR:ER ratio compared with approximately
70% for women with a lower ratio (Figure 1A; log-rank
P < 0.0001). Overall, 27% (6/22) of women with high
ratios remained disease free by the end of the study
or at the time they were censored compared with
72% (47/169) of women with low ratios. The DSS by
the end of the study was about 30% for women with
higher AR:ER ratios compared with about 60% for
those with lower ratios (Figure 1B; P < 0.0001). The
majority of women with high ratios (59%; 13/22) died
from their breast cancer during the study period; only
21% (36/167) of women with low ratios died (Figure 1B).
As shown in Figure 1C, there is a significant difference in
the time to recurrence, with patients having tumors with
high AR:ER ratio failing approximately 11 months earlier
than those with a low (<2) ratio. The significance does not
hold up for DSS; however, patients with high AR:ER ratios
died from their breast cancer on average 10 months earlier
than patients with low ratios (Figure 1D). The number of
patients at risk at each time point is reflective of the
number of patients censored due to no further follow-up
data at each time point (underneath Figure 1A,B,C,D).
Representative AR/ER staining in the <2 or ≥2 categories
is shown (Figure 1E).
To determine whether the AR:ER ratio was an inde-
pendent predictor of poor survival, a multivariate model
was used that took into account other factors known to
influence outcome. Variables included in a multivariate
analysis were age, grade, tumor size, ER percent staining,
and the dichotomized AR:ER ratio. AR percent staining
was not included in the model because it was not a
significant independent predictor of failure and it was
highly correlated with the AR:ER ratio (Spearman cor-
relation coefficient, r = 0.86, P < 0.0001). Collinearity was
tested for the predictor variables, particularly for ER
percent staining and the AR:ER ratio. The ratio as a con-
tinuous variable was moderately negatively correlated
Table 2 Univariate analysis for associations of variables with tamoxifen failure at 5 years, disease-free survival and
disease-specific survival for entire study period
Tamoxifen failure 5 years DFS overall DSS overall
Variable n HR (95% CI) P value HR (95% CI) P value HR (95% CI) P value
Age <50 16 1.00 1.00 1.00
Age ≥50 175 0.49 (0.22, 1.08) 0.08 0.69 (0.33, 1.46) 0.33 0.79 (0.33, 1.87) 0.58
Tumor size ≤2 cm 105 1.00 1.00 1.00
Tumor size >2 cm 86 1.92 (1.08, 3.42) 0.03 1.95 (1.18, 3.24) 0.01 2.39 (1.32, 4.31) 0.004
Tumor grade 1 15 1.00 1.00 1.00
Tumor grade 2 112 1.78 (0.42, 7.54) 0.43 1.33 (0.47, 3.74) 0.59 1.05 (0.37, 3.02) 0.92
Tumor grade 3 63 3.33 (0.78, 14.2) 0.10 2.05 (0.71, 5.90) 0.18 1.52 (0.51, 4.51) 0.45
LN-negative 63 1.00 1.00 1.00
LN-positive 83 3.41 (1.40, 8.31) 0.01 2.42 (1.19, 4.94) 0.02 2.12 (0.95, 4.75) 0.07
%ER, continuous 192 0.98 (0.98, 0.99) 0.0002 0.99 (0.98, 0.99) 0.0004 0.99 (0.98, 0.99) 0.001
AR = 0% 20 1.00 1.00 1.00
AR >0% 171 0.61 (0.27, 1.36) 0.23 0.91 (0.42, 2.01) 0.82 1.20 (0.43, 3.33) 0.73
AR/ER < 2 169 1.00 1.00 1.00
AR/ER≥ 2 22 4.43 (2.33, 8.42) <0.0001 4.40 (2.47, 7.83) <0.0001 3.66 (1.94, 6.93) <0.0001
PR-negative 22 1.00 1.00 1.00
PR-positive 108 0.43 (0.18, 1.04) 0.06 0.62 (0.27, 1.43) 0.26 0.69 (0.26, 1.84) 0.46
MIB-1 <21.3 93 1.00 1.00 1.00
MIB-1 ≥21.3 95 1.17 (0.66, 2.07) 0.59 0.98 (0.59, 1.61) 0.93 0.98 (0.55, 1.73) 0.94
Mitotic index number ≤4 94 1.00 1.00 1.00
Mitotic index number >4 92 1.64 (0.92, 2.94) 0.10 1.54 (0.93, 2.55) 0.10 1.34 (0.77, 2.37) 0.30
erbB2 ≤30% 152 1.00 1.00 1.00
erbB2 >30% 16 1.02 (0.36, 2.84) 0.98 0.71 (0.26, 1.96) 0.51 0.69 (0.22, 2.24) 0.54
EGFR = 0% 139 1.00 1.00 1.00
EGFR >0% 26 1.31 (0.60, 2.83) 0.50 1.01 (0.50, 2.07) 0.97 1.17 (0.54, 2.51) 0.70
AR, androgen receptor; CI, confidence interval; DFS, disease-free survival; DSS, disease-specific survival; EGFR, epidermal growth factor receptor; ER, estrogen receptor;
LN, lymph node; PR, progesterone receptor. Bold data are significant.
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was no evidence of collinearity based on variance infla-
tion analysis from linear regression models. Based on
the lack of evidence for collinearity, both variables were
included in the Cox models. Using a step-wise modeling
strategy, the final model for tamoxifen failure consisted
of the AR:ER ratio, ER percent staining and grade.
Women with AR:ER ratio ≥2.0 are nearly three times
more likely to fail tamoxifen therapy as compared with
women with a lower ratio (HR = 2.87, P = 0.04; Table 3).
This reflects the additional risk from the ratio above the in-
dependent effects of ER percent staining, as in this analysis
the results are adjusted by the percent of ER staining and by
grade. The AR:ER ratio continued to be an independent pre-
dictor of failure for DFS and DSS. The hazard ratio for the
dichotomized AR:ER ratio was higher for DFS (HR = 4.04,
P = 0.002). For DSS, the measure of effect was slightly
lower (HR = 2.75, P = 0.03). Both DFS and DSS models
were adjusted for ER percent staining and tumor size.To investigate whether the AR:ER ratio was merely a
reflection of the level of ER positivity, we tested various
cutoff points for ER% cell staining. Using 20% cell stain-
ing positive for the ER cutoff point, we determined that
although those patients with little ER were of course more
likely to have a high AR:ER ratio (10/15), there were
12/165 tumors with high ER levels that also had a
high AR:ER ratio (>2.0). A high AR:ER ratio is there-
fore not merely a consequence of low ER. In the multi-
variate setting, while the dichotomization of ER at <20%
versus ≥20% was significant alone, when the AR:ER ratio
was added ER percent cell staining lost its significance.
Androgens are proliferative in ER+/AR + breast cancer
lines and the AR signaling inhibitor enzalutamide
inhibits androgen-mediated proliferation and tumor
growth in vivo
Lysates from four luminal ER + breast cancer cell lines
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Figure 1 Women with tumors having a higher AR:ER ratio have a shorter disease-free and disease-specific overall survival as compared
with patients with lower AR:ER ratio. Immunohistochemistry for androgen receptor (AR) and estrogen receptor (ER) were performed on
formalin-fixed paraffin-embedded sections of primary breast cancers. Slides were scored for the percent of positive nuclear staining for AR and ER.
Ratios were calculated to determine the best cutoff point for analysis. For (A) to (D) women are divided into two groups: those with AR:ER ratios <2.0
(blue squares) and those with AR:ER ratios ≥2.0 (red circles). The number of patients at risk at each time point is reflective of the number of patients
censored due to no further follow-up data at each time point (underneath). Kaplan–Meier survival curve for: (A) disease-free survival (DFS) for all
patients; (B) disease-specific survival (DSS) overall for all patients; (C) DFS for patients who failed while on tamoxifen therapy; (D) DSS overall for
patients who failed while on tamoxifen therapy; and (E) representative images of AR and ER staining from the two groups (400× magnification).
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breast cancer cell line MDA-MB-453, which express high
levels of AR [20,28,29], were used as positive controls for
AR expression. MCF7 cells and the newly derived BCK4
cell line express both AR and ER (Figure 2A) and the new
androgen receptor signaling inhibitor enzalutamide
prevents ligand-mediated stabilization of AR protein in
MCF7 cells (Figure 2B). Both cell lines proliferate in
response to DHT (Figure 2C,D). Unlike androstenedione
and testosterone, DHT is not aromatizable to estrone orTable 3 Multivariate Cox proportional hazards models for tam
disease-specific survival for entire study period
n Events HR
Tamoxifen failure at 5 years 191* 48 2.8
DFS overall 191** 63 4.0
DSS overall 190** 49 2.7
AR, androgen receptor; CI, confidence interval; DFS, disease-free survival; DSS, disea
*One case was missing tumor grade.
**Missing outcome data.E2 [30-32]. DHT-stimulated proliferation was blocked
by enzalutamide in both the MCF7 and BCK4 lines
(Figure 2C,D). Enzalutamide inhibited DHT-mediated
nuclear translocation of AR within 3 hours as determined
by nuclear and cytosolic fractionation (Figure 2E).
To determine whether enzalutamide inhibits androgen-
mediated growth in vivo, MCF7 cells constitutively ex-
pressing luciferase (MCF7-TGL) were injected into the
mammary fat pad of ovariectomized mice implanted with
DHT pellets and the tumor burden was measured usingoxifen failure at 5 years, disease-free survival and
AR:ER ratio ≥ 2
95% CI P value Model adjusted by
7 1.08, 7.67 0.04 ER%, tumor grade
4 1.68, 9.69 0.002 ER%, tumor size
5 1.11, 6.86 0.03 ER%, tumor size
se-specific survival; ER, estrogen receptor. Bold data are significant.
Figure 2 Enzalutamide abrogates androgen mediated proliferation in estrogen receptor-positive breast cancer cells. (A) Baseline levels
of androgen receptor (AR) and estrogen receptor (ER) alpha protein in whole cell lysates from ER-positive (MCF7, BCK4, T47D and ZR-75-1) and
ER-negative (MDA-MB-453) breast cancer and prostate (LNCaP) cancer cell lines. (B) AR protein levels in MCF7 cells plated in charcoal-stripped
serum-containing media for 48 hours prior to treatment with vehicle control, 10 nM 5-alpha-dihydrotestosterone (DHT), 10 μM enzalutamide
(Enza) or a combination of DHT and Enza for 48 hours. (C) MCF7 and (D) BCK4 breast cancer cells, both ER + AR+, were treated with vehicle
control, 10 nM DHT, 10 μM Enza or a combination of DHT and Enza, and MTS proliferation assays were performed. Error bars represent standard
error of the mean. *P < 0.05, ***P < 0.001 for DHT versus DHT + Enza, analysis of variance with Bonferroni’s multiple comparison test correction.
(E) AR levels in cytosolic and nuclear fractions of MCF7 cells treated with vehicle, 10 nM DHT, 10 μM enzalutamide or DHT + Enza for 3 hours.
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tumors were established, mice were matched based upon
tumor imaging (day −2) into two treatment groups, one
receiving control chow and the other receiving chow
containing 50 mg/kg enzalutamide on day 0. Tumors in
the DHT-treated mice on control chow continued to
grow, while mice receiving DHT plus enzalutamide
showed regression of tumors by the in vivo imaging
system (Figure 3A) and caliper measurement (data not
shown). On the final day of imaging (day 19), tumors had
regressed to near undetectable levels, with an 83.2% de-
crease in luminescence in mice receiving DHT plus enza-
lutamide as compared with the DHT group (Figure 3A,B).
As determined by BrdU incorporation and immunostain-
ing, proliferation in the enzalutamide-treated tumors
was 31.3% lower than in tumors treated with DHT
alone (Figure 3C). TUNEL staining indicated a 50%increase in apoptotic cells in enzalutamide-treated tumors
(Figure 3D). A dramatic (92.5%) decrease in AR nuclear
localization was observed in the tumors treated with
enzalutamide (Figure 3E), consistent with the ability of
enzalutamide to impair nuclear entry of AR in prostate
cancer [33]. Similar results to the above with MCF7
xenografts were obtained in mice administered enzalu-
tamide by oral gavage, where tumor burden decreased in a
dose-dependent manner (data not shown).
Enzalutamide inhibits androgen-mediated growth in
ER– breast cancer cells in vitro and in vivo
The MDA-MB-453 breast cancer cell line represents
the ER– molecular apocrine or luminal androgen re-
ceptor subtype of breast cancer with high levels of
AR [17,18,20,34]. In this line, AR contains a point
mutation (Q865H) reported to decrease sensitivity to
Figure 3 Enzalutamide inhibits androgen-stimulated growth of MCF7 tumors in vivo. MCF7-TGL cells stably expressing luciferase were
implanted orthotopically in the mammary gland of NOD/SCID ovariectomized female mice with a 5-alpha-dihydrotestosterone (DHT) pellet
implanted subcutaneously. Mice were matched into two groups based on tumor volume (day −2) and treatment with either control chow (DHT)
or chow containing 50 mg/kg enzalutamide (DHT + Enza) begun (day 0, indicated by arrow), and the tumor burden was measured by whole-body
luminescence. (A) Mean total flux of all mice in each of the treatment groups. Error bar represents standard error of the mean. *P < 0.05, Wilcoxon
rank sum. (B) Total luminescent flux is shown for all individual mice at the day of matching (day −2) and at the final imaging day (day 19). *P < 0.05,
Wilcoxon rank sum. (C) Mice were injected with bromodeoxyuridine (BrdU) 2 hours prior to sacrifice and BrdU immunohistochemistry was performed on
formalin-fixed paraffin-embedded tumor sections and quantified. *P< 0.05, Student’s t test. Representative images of BrdU staining (400× magnification)
and quantification. (D) Quantification of apoptotic cells as measured by terminal deoxynucleotidyl transferase dUTP nick end-labeling (TUNEL) staining
with representative images below (400× magnification). *P< 0.05, Student’s t test. (E) Quantification of nuclear AR staining and representative images
(400× magnification). ***P< 0.001, Wilcoxon rank sum.
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to androgens [28,29] and we therefore sought to deter-
mine whether enzalutamide could block DHT-mediated
effects on proliferation and gene expression. Indeed,
enzalutamide completely abrogated proliferation inducedby DHT (Figure S2A in Additional file 2) and expression
of known AR-regulated genes [29], such as fatty acid
synthase, gross cystic disease fluid protein (also called
prolactin inducible protein) and prolactin receptor, was
reduced by enzalutamide (Figure S2B in Additional file 2).
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androgen responsive luciferase reporter (MDA-kb2) [36],
enzalutamide inhibited luciferase reporter activity in a
dose-dependent manner (Figure S2C in Additional file 2).
Enzalutamide impairs ligand-mediated nuclear import of
AR in prostate cells [33], and in MDA-kb2 cells it reduced
the ratio of nuclear to total AR (Figure S2D in Additional
file 2). Immunoblotting for AR in nuclear and cytoplasmic
lysates demonstrates that the same is true in wild-type
MDA-MB-453 cells (Figure S3 in Additional file 3).
To determine whether enzalutamide inhibits andro-
gen-induced tumor growth of ER– breast cancer cells,
MDA-MB-453 xenografts were grown at the orthotopic
site in mice implanted with a DHT pellet and the tumor
size was measured by caliper. Once tumors reached
100 mm3, mice were treated with 10 mg/kg/day enzalu-
tamide or vehicle by oral gavage (Figure 4A, green
arrow). DHT stimulates tumor growth as previously
reported [20], but in mice treated with DHT plus enza-
lutamide (10 mg/kg by oral gavage) tumors did not
significantly differ from mice that received vehicle control
(Figure 4A). Another group of mice received a higher dose
of enzalutamide (25 mg/kg/day) starting when tumors
reached an average of 400 mm3 (Figure 4A, blue arrow).
At this higher dose, there was a trend towards decreased
tumor size, although this did not reach statistical signifi-
cance (Figure 4A). Tumor weights in either the low-dose
or high-dose enzalutamide treatments were significantly
lower than mice treated with DHT only, an 85.2% and
65.0% decrease respectively (Figure 4B), indicating that
the caliper measurements for a high dose of enzalutamide
underestimates the decreased tumor burden in this group.
Interestingly, there was a statistically significant increase
in apoptosis in both enzalutamide treatment groups
versus DHT (60.0% and 54.3% increase in low-dose and
high-dose groups respectively), as measured by cleaved
caspase 3 (Figure 4C, quantification on left and repre-
sentative images on right), but there was no difference in
the proliferation rate of any of the groups, as measured
by Ki67 staining (not shown). Thus, in MDA-MB-453
tumors, DHT protects cells against apoptosis and
enzalutamide impairs this anti-apoptotic effect. Con-
sistent with the in vitro data, enzalutamide decreased
ligand-mediated nuclear entry of AR such that there
is a significant decrease (50.0% in low dose and 44.3%
in high dose) in the number of AR-positive nuclei in
the enzalutamide-treated tumors (Figure 4D, quantifi-
cation on left and representative images on right).
Similarly, when an MDA-MB-453 xenograft study was
performed with low-dose and high-dose enzalutamide
treatments initiated when the tumors reached 100 mm3
(Figure S4A in Additional file 4), tumor growth was
decreased in a dose-dependent manner (Figure S4B in
Additional file 4) and was associated with significantlyreduced nuclear AR staining in enzalutamide-treated
tumors (Figure S4C in Additional file 4). Steady-state
concentrations of enzalutamide, including the pharma-
cologically active metabolite N-desmethyl-MDV3100, in
the MDA-MB-453 xenograft studies were only moderately
lower than what has been reported in patients receiving
160 mg/day enzalutamide (Cmax values for enzaluta-
mide and the pharmacologically active metabolite, N-
desmethyl enzalutamide, were 16.6 μg/ml and 12.7 μg/ml,
respectively).
Enzalutamide inhibits estrogen mediated growth in vitro
and in vivo
While enzalutamide has high affinity binding for AR,
it does not significantly bind to either ERα or ERβ as
determined by ligand binding assays (Table S1 in Additional
file 5). However, originally as a negative control in experi-
ments where we were antagonizing DHT with enzaluta-
mide, we combined enzalutamide with E2 in ER+/AR +
breast cancer cells. Surprisingly, enzalutamide significantly
inhibited E2-induced proliferation of both MCF7 and
BCK4 cells in vitro (Figure 5A,B). Enzalutamide also
inhibited E2-induced upregulation of PR and SDF-1,
two estrogen-responsive genes (Figure 5C). In stark
contrast, although bicalutamide effectively inhibited
DHT-mediated proliferation in MCF7 cells (Figure 5D),
it had the opposite effect on E2 signaling, as it significantly
increased E2-mediated proliferation (Figure 5E) and in-
creased the E2-mediated induction of PR and SDF-1
mRNA (Figure 5F).
To determine the effect of enzalutamide on E2-stimu-
lated breast tumor growth in vivo, a xenograft study was
performed injecting MCF7-TGL cells in ovariectomized
mice implanted with an E2 pellet. Cells were injected
orthotopically and once tumors were established (arrow,
average size of 100 mm3), mice were matched into three
groups: control chow; control chow and a tamoxifen
pellet; and chow containing 50 mg/kg enzalutamide
(Figure 6A). Enzalutamide significantly inhibited E2-
mediated MCF7 tumor growth as effectively as tamoxi-
fen, with a decrease in tumor luminescence of 59.9% for
the tamoxifen group and 70.3% in the enzalutamide
group at day 11. Day 11 was the final day of imaging for
the E2-only group since these mice had to be euthanized
due to tumor burden. Luminescence flux for individual
animals (Figure 6B) and images of mice (Figure 6C) are
shown for the day of matching (day −3) and the last
imaging day when all mice were alive (day 11). Both
drugs significantly decreased cell proliferation, with a
46.4% decrease in the E2 plus tamoxifen group and a
54.2% decrease in the E2 plus enzalutamide group com-
pared with the E2 group, as measured by BrdU incorpor-
ation (Figure 6D). In contrast to what was observed in
DHT-mediated tumor growth, enzalutamide did not
Figure 4 Enzalutamide inhibits androgen-stimulated growth of MDA-MB-453 tumors. MDA-MB-453 cells were injected orthotopically in the
mammary gland of female NOD-SCID-IL2Rgc−/− mice. Three groups had a 5-alpha-dihydrotestosterone (DHT) pellet implanted subcutaneously
and one group had no pellet (Vehicle). Once tumors reached an average size of 100 mm3 (green arrow), mice were given either enzalutamide
(Enza, 10 mg/kg) or vehicle (Vehicle and DHT groups) by daily oral gavage. Another group was given a higher dose of Enza (25 mg/kg) by oral
gavage when tumors reached an average size of 400 mm3 (blue arrow). (A) Tumor volume was measured weekly by caliper. Error bars represent
standard error of the mean. *P < 0.05, **P < 0.01 for DHT versus DHT + Enza (10 mg/kg), Wilcoxon rank sum. (B) Tumors were excised and weighed
at the end of the experiment. (C) Tumor sections stained for cleaved caspase 3 were quantified (left) and representative images shown (right)
(200× magnification). *P < 0.05, **P < 0.01, ***P < 0.001, analysis of variance with Bonferroni’s multiple comparison test correction. (D) Nuclear
androgen receptor staining was quantified (left) and representative images (400× magnification) are shown (right). *P < 0.05, ***P < 0.001,
Kruskal–Wallis with Dunn’s multiple comparison test correction.
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(data not shown). Interestingly, ER protein levels in the
MCF7 xenograft tumors were affected differently by
tamoxifen versus enzalutamide (Figure S5 in Additional
file 6). ER immunostaining was quantified with ImageJ
and by pathologist (PJ) scoring in a blinded mannerfor percent cells positive for nuclear ER. By both
methods, ER was extremely low in the E2-alone group,
but significantly increased with the addition of tamoxifen.
However, in the E2 plus enzalutamide group, ER levels
are not significantly different from E2 alone, indicating
that enzalutamide does not elicit upregulation of ER
Figure 5 Enzalutamide inhibits estradiol-mediated proliferation of breast cancer cells, while bicalutamide does not. MTS proliferation
assays were performed on (A) MCF7s cells and (B) BCK4 cells treated with vehicle control, 10 nM estradiol (E2), 10 μM enzalutamide (Enza) or a
combination of E2 and Enza. Error bars represent standard error of the mean (SEM). **P < 0.01, ***P < 0.001 for E2 versus E2 + Enza, analysis of
variance (ANOVA) with Bonferroni’s multiple comparison test correction. (C) MCF7 cells were treated for 48 hours with treatments as above and
real-time polymerase chain reaction (PCR) was performed for estrogen-responsive genes, progesterone receptor (PR) and stromal cell-derived
factor 1 (SDF-1, also known as CXCL12). Each gene is normalized to 18S and shown relative to vehicle. *P < 0.05, ***P < 0.001, Student’s t test. MCF7
cells were treated with vehicle control, (D) 1 μM bicalutamide, 10 nM 5-alpha-dihydrotestosterone (DHT) and DHT + bicalutamide or (E) with 10 nM E2
and E2 + bicalutamide. **P < 0.01, ***P < 0.001 for DHT versus DHT + bicalutamide, or E2 versus E2 + bicalutamide, ANOVA with Bonferroni’s multiple
comparison test correction. (F) MCF7 cells treated for 48 hours with vehicle, 1 μM bicalutamide, 10 nM E2 and E2 + bicalutamide and real-time PCR
performed for PR and SDF-1. *P < 0.05, ***P < 0.001, Student’s t test. Error bars represent SEM, Student’s t test (all analyses).
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suggests that enzalutamide affects ER by a different
mechanism than the competitive antagonist tamoxifen.
This intriguing finding will be the focus of a subsequent
study.
Importantly, mean animal weights during and at the
end of all in vivo studies showed no differences across
treatment groups, indicating no adverse effects on the
general health of the mice (Figure S6 in Additional file 7).Discussion
The vast majority of ER + breast cancers are clearly also
AR + (84 to 91%) [5,37,38] and patients with tumors that
co-express AR with ER and PR have a longer DFS than
those with tumors negative for all three receptors [37],
probably reflecting a more well-differentiated state than
that of receptor-negative tumors . However, the question
of whether androgens and ARs are harmful or beneficial
for patients with breast cancer is complex [39-41] and
Figure 6 Enzalutamide inhibits estrogen-stimulated growth of MCF7 tumors as effectively as tamoxifen. MCF7-TGL cells stably expressing
luciferase were implanted orthotopically in the mammary gland of ovariectomized female nude mice. All mice had an estradiol (E2) pellet
implanted subcutaneously and were given either control chow (E2), control chow plus a tamoxifen pellet implanted subcutaneously (E2 + Tam)
or chow containing 50 mg/kg enzalutamide (E2 + Enza). The tumor burden was measured by whole-body luminescence. (A) Mean total flux.
Mice were matched on day −3 and treatment began on day 0 (arrow). *P < 0.05, analysis of variance (ANOVA) with Bonferroni’s multiple comparison
test correction. (B) The total luminescent flux is shown for individual mice on the day of matching (day −3) and of final imaging (day 11). *P < 0.05,
ANOVA with Bonferroni’s multiple comparison test correction. (C) Images of luminescent signal in the two treatment groups at time of matching
(day −3) and the final day of imaging (day 11). (D) Mice were injected with bromodeoxyuridine (BrdU) 2 hours prior to sacrifice and immunohistochemistry
for BrdU was performed on tumor sections and quantified using imageJ (National Institutes of Health, Bethesda, MD, USA). Representative images of
BrdU staining (left, 400× magnification) and quantification (right). **P < 0.01 for E2 versus E2 + Tam, ***P < 0.001 for E2 versus E2 + Enza, ANOVA with
Bonferroni’s multiple comparison test correction.
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breast cancer subtype.
Our analysis of 192 women with ER + breast cancers
treated with tamoxifen revealed that rather than the level
of AR expression, the AR:ER ratio may play a role in dis-
ease progression and response to treatment. In our cohort,
women with tumors expressing a high ratio of AR:ER
(≥2.0) had over four times the risk for failure while on
tamoxifen (HR = 4.43) compared with women with a low
ratio (<2.0). When ER percent cell staining was added to
the model, the risk dropped to 2.87-fold, showing thatalthough ER percent staining explained some of the
increase in risk from a higher ratio, the AR:ER ratio actu-
ally has an independent effect on risk for failure above ER
percent staining. In summary, the data indicate that a high
ratio of nuclear AR to ER protein is indicative of shorter
time to relapse in patients treated with tamoxifen, and
may also be indicative of a lack of response to neoadjuvant
AI treatment. Although they need to be tested in
additional cohorts, these provocative findings suggest that
the AR:ER ratio may be a new, independent predictor of
response to traditional E2/ER-directed endocrine
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that relapse while on tamoxifen or AIs might be good
candidates for AR-directed therapy. Lastly, AR:ER ra-
tio is also an independent predictor of DFS (HR = 4.04,
95% confidence interval: 1.68, 9.69; P = 0.002) and DSS
(HR = 2.75, 95% confidence interval: 1.11, 6.86; P = 0.03).
Our in vitro and preclinical results demonstrate that
enzalutamide inhibits androgen-stimulated growth of
both ER+/AR + and ER–/AR + breast tumors. Surpris-
ingly, with regard to E2-mediated proliferation, enzaluta-
mide, which works by impairing androgen-mediated AR
nuclear entry, gives a completely different result than
the traditional anti-androgen, bicalutamide. Although
DHT is clearly proliferative in MCF7 and BCK4 cells, in
some breast cancer cell lines DHT decreased E2-
induced proliferation [28,42-44]; however, the antagonist
bicalutamide consistently increased E2-mediated pro-
liferation. This bicalutamide-mediated increase in E2-
stimulated proliferation was interpreted as indicating
that AR is protective against E2-mediated breast cancer
cell proliferation. However, we now present contrasting
results demonstrating that inhibition of AR with enzalu-
tamide decreases ER-mediated proliferation. A critical
difference between the two drugs is that while bicalu-
tamide permits AR nuclear entry, enzalutamide greatly
impairs AR localization and ligand-mediated stabilization,
as indicated in studies in prostate cancer and our nuclear
and cytosolic fractionation and immunohistochemistry in
xenograft tumors presented in this study. Our results with
enzalutamide thus shed new light on the role of AR in
breast cancer, since in vitro and in vivo preclinical studies
demonstrate that inhibiting AR nuclear localization de-
creases both androgen and estrogen-stimulated tumor
growth.
We propose an explanation that reconciles conflicting
reports regarding the role of AR in breast cancer by
recognizing that hormonal influences on the breast are
quite different in premenopausal versus postmenopausal
women. Data suggesting a protective effect of androgens
studied androgen in the presence of estrogen, thereby
more closely modeling the premenopausal state [45]
where androgens and AR may be protective against E2-
mediated proliferation. AR can bind to the ER cofactor
FOXA1 and to estrogen response elements, albeit as a
weaker transcriptional activator than ER at these loci;
therefore, the net effect of liganded AR competing with
liganded ER may be decreased E2-mediated proliferation
[42]. Additionally, in ER–/AR + tumors such as the
MDA-MB-453 cell line, global AR binding events largely
overlap that of ER in ER + luminal A tumors [19]. In
contrast, in postmenopausal women with ER + breast
cancer (which represent the majority of cases), and par-
ticularly in those being treated with AIs, circulating
levels of E2 are extremely low, while circulating androgenlevels are slightly elevated since AIs block the conversion
of androgens to estrogen [12]. Importantly, circulating
levels of testosterone, androstenedione, and DHEA-S
increase in women on AI therapy [13] as compared with
pretreatment levels. Furthermore, high levels of the
adrenal androgen DHEA-S before treatment are predictive
of failure on AIs and circulating DHEA-S increased during
treatment in patients with tumors that failed to respond
to AI treatment [14]. In the context of a postmenopausal
woman on AI therapy (in the absence of estrogen), it is
possible that activated AR could mediate protumorigenic
pathways in breast cancers. As recently reviewed [40,46],
the data in cell lines regarding whether DHT is prolifera-
tive are very conflicting; however, a study with seven lines
derived from ductal carcinomas demonstrated that the
majority were growth stimulated by physiologic levels of
testosterone [47]. Interestingly, local production of sex
steroids can occur, and DHT levels have been found to be
significantly higher in carcinomatous breast tissues than in
the blood of postmenopausal breast cancer patients [48].
DHT is not aromatizable [31,32,49], indicating that
conversion to estrogens is not causing breast tumor
growth in our study. Furthermore, we observe that enza-
lutamide acts differently when it opposes DHT versus
E2-driven tumor growth. Enzalutamide very effectively
blocks DHT-mediated protection against apoptosis in
both ER + and ER– tumors, but it inhibits proliferation
but does not affect apoptosis when opposing E2-stimulated
tumor growth in ER+/AR +models. Although enzaluta-
mide does not bind ER, it appears to affect ER in MCF7
xenograft tumors, but in a different manner than tam-
oxifen. Furthermore, we find that enzalutamide blocks
the E2-mediated induction of ER-regulated genes such
as the chemokine SDF-1 (also known as CXCL12).
SDF-1 mediates the mitogenic effects of E2 in breast
cancer cells [50]. The SDF-1/CXCR4 pathway can acti-
vate ER via phosphorylation, and E2-driven proliferation
is blocked by inhibition of this pathway [51]. SDF-1
promotes the growth of prostate epithelial cells by pro-
moting the nuclear localization of AR, binding of AR to
DNA and increased PSA protein in a ligand independent
manner [52]. In contrast to enzalutamide, bicalutamide
enhances upregulation of SDF-1 and other E2-regulated
genes, and enhances E2-mediated breast cancer cell
proliferation. This difference in how enzalutamide and
bicalutamide affect ER activity may provide insight into
the role of AR in breast cancer. When bound to bica-
lutamide, AR can still translocate to the nucleus and
bind to DNA [22]. In contrast, enzalutamide has been
reported to impair liganded AR nuclear entry in prostate
cancer cells [33,53], as we see in this study in breast can-
cer cell lines in culture and xenografts. Our observation
that enzalutamide blocks E2-induced proliferation and
inhibits liganded ER activity on classical ER-regulated
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function. Indeed, AR and ER can directly interact in
breast cancer cells [54,55].
Conclusion
While AR has been considered a potential therapeutic target
in ER–/AR+ breast cancers [2,17,18,20], it has not previ-
ously been suggested as a target in ER + breast cancers. Our
data in clinical specimens suggest that the ratio of nuclear
AR to ER may critically influence tumor biology and re-
sponse to endocrine therapy. A high AR:ER ratio may be
predictive of suboptimal response to ER-directed endocrine
therapy. Furthermore, higher nuclear expression of AR rela-
tive to ER may also be indicative of active AR, since AR
translocates to the nucleus and is stabilized upon ligand
binding. AR and ER are expressed at roughly equivalent
amounts in tumors that respond to neoadjuvant endocrine
therapy and in adjacent uninvolved epithelium, suggesting
that similar levels of AR and ER reflect a more normal state.
In addition to being a predictor of poorer response to trad-
itional endocrine therapy and overall DFS, high levels of AR
relative to ER may also identify a subset of breast cancers
that would respond more favorably to enzalutamide alone
or combined with tamoxifen or AIs. Targeting AR may
prove useful in patients with recurrent ER + disease. If the
long-term selective pressure of drugs targeting the E2/ER
pathway leads to tumors switching to dependence on andro-
gens, initial treatment with both AI and enzalutamide may
be beneficial. In summary, our preclinical data support the
initiation of clinical studies evaluating enzalutamide for
treatment of AR+ tumors regardless of ER status, since
enzalutamide uniquely blocks both androgen-mediated and
estrogen-mediated tumor growth. Recently, a mutation was
discovered in AR that confers resistance to enzalutamide
and another new generation anti-androgen, ARN-509,
[56,57]. Whether such mutations will also arise in breast
cancer patients treated with anti-androgens remains to be
seen.Additional files
Additional file 1: Figure S1. Showing breast tumors that respond to
endocrine therapy tend to have decreased AR expression while nonresponders
tend to maintain AR expression. There is a positive correlation between AR and
ER in responsive tumors and uninvolved adjacent epithelium. Patients received
4 months of neoadjuvant endocrine therapy (exemestane or exemestane +
tamoxifen). Core biopsies taken prior to treatment (pre) and a tumor sample at
the time of surgery (post) were stained for AR expression. Graph depicts the AR
score (percent cells positive for nuclear AR staining versus intensity) in the pre
and post treatment samples for those who responded to the endocrine
therapy versus nonresponders. P= 0.064, Wilcoxon matched-pair test (left top).
Staining of AR in representative responsive and nonresponsive tumors pre
versus post treatment is shown below (400× magnification) (left, bottom). In
the same tumors, staining score (percent positive staining × intensity) for
nuclear AR was plotted on the y axis and ER on the x axis for patients
who responded (A, graph) versus those who did not (B, graph). Normal
uninvolved glands adjacent to tumors were scored for AR and ER (C, graph).The slope of the line (β) is indicated, as well as the P value, Spearman
correlation. Representative images of AR and ER staining (400× magnification)
in responders (A, right), nonresponders (B, right) and normal adjacent (C, right)
(1,000× magnification).
Additional file 2: Figure S2. Showing that enzalutamide (Enza)
abrogates DHT-mediated proliferation in ER-negative breast cancer cells. (A)
MTS proliferation assays were performed in MDA-MB-453 cells treated with
vehicle, 10 nM DHT, 10 μM Enza or DHT + Enza. Error bars = standard error
of the mean (SEM). (B) Real-time polymerase chain reaction for androgen
responsive genes fatty acid synthase (FASN), gross cystic disease fluid
protein (GCDFP-15, also called prolactin inducible protein) and prolactin
receptor (PRLR) was performed from RNA harvested from MDA-MB-453
breast cancer cells treated with vehicle, 10 μM Enza, 10 nM DHT or DHT +
Enza for 24 hours. Genes normalized to 18S and relative to vehicle. *P < 0.05,
**P < 0.01 for Student’s t test. (C) MDA-k2b cells, which contain an androgen
responsive luciferase construct, were treated for 24 hours with various
concentrations of DHT alone or in combination with 1 or 10 μM Enza prior
to luciferase assay, and luciferase units relative to the 0.001 nM DHT are shown.
Error bars = SEM. (D) MDA-kb2 cells were treated as indicated for 3 hours.
Nuclear and total AR staining was quantified with graph indicating the ratio of
nuclear to total AR (each triangle represents one cell). Representative images
(600× magnification). For proliferation and luciferase assays and the
quantification of nuclear/total AR ratio, *P< 0.05, **P< 0.01, ***P< 0.001 for
DHT versus DHT + Enza, analysis of variance with Bonferroni’s multiple
comparison test correction.
Additional file 3: Figure S3. Showing that enzalutamide (Enza) impairs
DHT-mediated nuclear entry of AR in apocrine breast cancer cells. MDA-453
cells were treated with vehicle, 10 nM DHT, 10 μM enzalutamide or DHT +
Enza for 3 hours. After nuclear and cytoplasmic fractionation, lysates were
immunoblotted for AR, Topo I (control for nuclear fraction) and glyceraldehyde
3-phosphate dehydrogenase (GAPDH; control for cytoplasmic fraction).
Additional file 4: Figure S4. Showing that enzalutamide (Enza) inhibits
androgen-mediated growth of MDA-MB-453 tumors. MDA-MB-453 cells
were injected orthotopically in the mammary gland of female NOD-SCID-
IL2Rgc−/− mice. Three groups had a DHT pellet implanted subcutaneously
and one group had no pellet (Vehicle). Once the tumors reached 100 mm3,
the mice were given vehicle (Vehicle and DHT groups) or Enza at 10 mg/kg
or 25 mg/kg, by daily oral gavage. (A) Tumor volume was measured
weekly by caliper. Error bars represent standard error of the mean. *P < 0.05,
**P < 0.01, ***P < 0.001 for DHT versus DHT + Enza (10 mg/kg) and DHT +
(25 mg/kg), Wilcoxon rank sum. (B) Tumors were excised and weighed at
the end of the experiment. ***P < 0.001, analysis of variance with Bonferroni’s
multiple comparison test correction. (C) Tumor sections stained for AR.
Nuclear AR staining was quantified and representative images (200×
magnification) are shown below. *P< 0.05, Kruskal–Wallis with Dunn’s
multiple comparison test correction.
Additional file 5: Table S1. Presenting the competitive radioligand
binding assay with enzalutamide competing with 0.5 nM [3H] estradiol
for binding to ERα and ERβ. The competing reference ligand was 1 μM
diethylstilbestrol, which gave 50% inhibition at 0.5 nM on ERα and 0.9 nM
on ERβ, while enzalutamide at concentrations up to 100 mM only gave
between 1 and 4% inhibition on ERα and between 1 and 6% on ERβ.
Additional file 6: Figure S5. Showing that enzalutamide (Enza)
affects ER protein differently than tamoxifen in vivo in MCF7 xenografts.
Immunohistochemical staining of ER performed on formalin-fixed
paraffin-embedded MCF7 tumor sections (n = 8 E2 and E2 + TAM, and
n = 9 E2 + Enza) scored by pathologist for (A) percent positive nuclear
staining (**P < 0.005) and (B) intensity. (C) Overall percent positive signal
quantified by ImageJ. *P < 0.05. (D) Representative images at 1,000 ×.
Additional file 7: Figure S6. Showing that treatments did not affect
mouse body weights in any of the three xenograft experiments. Average
mouse weights in grams for (A) mice with MCF7 xenografts in the E2,
E2 + enzalutamide (Enza), and E2+ tamoxifen (Tam) treatment groups at
the end of the study (day 11); (B) mice with MCF7 xenografts in the DHT
versus DHT + Enza treatment groups at the end of the study (day 19);
and (C) mice with MDA-MB-453 xenografts treated with vehicle, DHT
alone, DHT + 25 mg/kg MDV3100 (Enza), or DHT + 10 mg/kg MDV3100
(Enza) throughout the experiment.
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